MOLN MOLECULAR PARTNERS AG IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1745114 · Reporting currency CHF · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CHF | 2025Q2*2025-06-30 | 2024Q2*2024-06-30 | 2023Q2*2023-06-30 | 2022Q2*2022-06-30 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 0 | 1.55M | 415,000 | 11.76M |
| R&D expense | 10.71M | 13.09M | 11.63M | 12.57M |
| SG&A expense | 3.99M | 4.44M | 4.67M | 5.48M |
| Operating income | -17.32M | -15.98M | -15.88M | -6.29M |
| Interest expense | 3.50M | 18,000 | 1.19M | 241,000 |
| Pretax income | -20.40M | -15.08M | -15.99M | -4.52M |
| Income tax | 0 | 0 | 0 | 0 |
| Net income | -20.40M | -15.08M | -15.99M | -4.52M |
| EPS (basic) | -0.56 | -0.46 | -0.49 | -0.14 |
| EPS (diluted) | -0.56 | -0.46 | -0.49 | -0.14 |
| Weighted avg. shares (diluted) | 37.39M | 33.18M | 32.83M | 32.50M |
| Balance sheet | ||||
| Cash & equivalents | 81.97M | 64.06M | 63.24M | 114.94M |
| Short-term investments | 32.51M | 93.44M | 154.95M | 170.12M |
| Receivables | 3.60M | 3.37M | 1.51M | 2.58M |
| Current assets | 120.57M | 165.60M | 223.86M | 291.49M |
| PP&E, netmay include right-of-use assets (IFRS) | 3.68M | 4.89M | 6.36M | 7.52M |
| Intangibles | 10,000 | 122,000 | 277,000 | 291,000 |
| Total assets | 124.25M | 170.62M | 230.49M | 299.29M |
| Current liabilities | 12.90M | 11.36M | 15.67M | 23.31M |
| Total liabilities | 17.59M | 15.05M | 24.52M | 33.42M |
| Shareholders' equity | 106.66M | 155.57M | 205.98M | 265.87M |
| Cash flow statement | ||||
| Operating cash flow | — | — | — | — |
| Stock-based compensation | 1.23M | 1.13M | 1.31M | 1.52M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.